TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8101011

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study: 3826569

Group type: EXPERIMENTAL
Intervention: Nerve Stimulator Technique (NST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Perivascular Catheter Technique (PVT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study: 30012116

Group type: EXPERIMENTAL
Intervention: 3-month evidence-based behaviour change program via the TRavelVU Plus app
Number of subjects: 250

Group type: COMPARATOR
Intervention: Monitoring of active transport via the TRavelVU app
Number of subjects: 250
Study: 27015966

Group type: EXPERIMENTAL
Intervention: Panic and Smoking Reduction Treatment (PSRT) + d-cycloserine (DCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panic and Smoking Reduction Treatment (PSRT) + placebo
Number of subjects: 0
Study: 24496783

Group type: EXPERIMENTAL
Intervention: CPAP at 5‐7 cm H2O during the first 6 h after surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Venturi mask supplemental oxygen
Number of subjects: 110
Study: 22622911

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic and steroids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic only
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections (unspecified)
Number of subjects: 16
Study: 19826409

Group type: EXPERIMENTAL
Intervention: FOBT delivered by mail
Number of subjects: 26255

Group type: EXPERIMENTAL
Intervention: FOBT delivered by GP/screening facility
Number of subjects: 26255

Group type: EXPERIMENTAL
Intervention: Once‐only sigmoidoscopy
Number of subjects: 26255

Group type: EXPERIMENTAL
Intervention: FS followed by FOBT for screenees with negative FS
Number of subjects: 26255

Group type: EXPERIMENTAL
Intervention: Patient's choice between FS and FOBT
Number of subjects: 26255
Study: 18050178

Group type: COMPARATOR
Intervention: Intervention group I (information on arthritis self-management through GPs)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Intervention group II (information on arthritis self-management + additional case management via telephone by practice nurse)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1021
Study: 16075363

Group type: EXPERIMENTAL
Intervention: Adjuvant oral clodronate (1.6 g/day) for 3 years
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 299
Study: 12365910

Group type: EXPERIMENTAL
Intervention: Macular translocation with 360° peripheral retinectomy and silicone oil tamponade
Number of subjects: 15
Study: 10189133

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 10 mg twice daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus octreotide 150 microg (subcutaneously thrice daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus octreotide
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide
Number of subjects: 135
Study: 8944997

Group type: EXPERIMENTAL
Intervention: Leukocyte filters
Number of subjects: 50

Group type: COMPARATOR
Intervention: No leukocyte filters
Number of subjects: 50
Study: 1955654

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg every 12 hours for 3 days (first dose 800 mg)
Number of subjects: 38
Study: 6814284

Group type: EXPERIMENTAL
Intervention: Intranasal immunotherapy with Glu‐Rye (10-week course)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intranasal immunotherapy with Glu‐Rye
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30670004

Group type: EXPERIMENTAL
Intervention: Lower limb lifting exsanguination technique (Group A)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Squeeze exsanguination method (Group B)
Number of subjects: 236
Study: 28431533

Group type: EXPERIMENTAL
Intervention: Bikram yoga intervention (3-5 classes per week for 16 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 63
Study: 25689245

Group type: EXPERIMENTAL
Intervention: Regular insulin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Glargine insulin
Number of subjects: 42
Study: 23597356

Group type: EXPERIMENTAL
Intervention: Legacy for Children intervention (parenting groups for 3 to 5 years)
Number of subjects: 574
Study: 21494767

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19139439

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (15 weeks) followed by surgery (arm A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (arm B)
Number of subjects: 126
Study: 16815649

Group type: COMPARATOR
Intervention: SIPPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VG
Number of subjects: 0
Study: 15084982

Group type: EXPERIMENTAL
Intervention: PR-350
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 11439795

Group type: EXPERIMENTAL
Intervention: Blind intubation using the intubating laryngeal mask airway (blind‐ILM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fibreoptic-guided orotracheal intubation using an Ovassapian airway (FOS‐OA)
Number of subjects: 54
Study: 9564208

Group type: EXPERIMENTAL
Intervention: Fluoxetine (N = 8)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (N = 9)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo (combined sample of 17 cocaine-abusing depressed alcoholics)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cocaine-abusing depressed alcoholics (N = 17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-cocaine abusing depressed alcoholics (N = 34)
Number of subjects: 51
Study: 9301387

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2795873

Group type: EXPERIMENTAL
Intervention: Temperature-based, rate-modulated pacing
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-rate modulated pacing
Number of subjects: 3
Study: 363434

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (SRO) once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional oxprenolol (CO) once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (SRO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Morning dosing of SRO
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Evening dosing of SRO
Number of subjects: 16
Study: 31169381

Group type: EXPERIMENTAL
Intervention: ROOTS intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embedded assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention intensity
Number of subjects: 0
Study: 28809610

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m2 (C20)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Cabazitaxel 25 mg/m2 (C25)
Number of subjects: 1200
Study: 26299196

Group type: COMPARATOR
Intervention: XP (6 cycles of capecitabine)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: XPRT (2 cycles of XP + RT 45 Gy/25 fraction with capecitabine + 2 cycles of XP)
Number of subjects: 458

Group type: COMPARATOR
Intervention: XP
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: XPRT
Number of subjects: 458
Study: 23441835

Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 10
Study: 21221689

Group type: EXPERIMENTAL
Intervention: Anakinra plus MTX
Number of subjects: 54

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 54
Study: 19422435

Group type: EXPERIMENTAL
Intervention: Sensory retraining
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no sensory retraining)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Type of surgery
Number of subjects: 186
Study: 17719468

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 6 months followed by 6 months of single-blind Val in both groups
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 76
Study: 15064638

Group type: EXPERIMENTAL
Intervention: Endoscopic culture after acute infectious exacerbations of chronic rhinosinusitis
Number of subjects: 113

Group type: COMPARATOR
Intervention: Baseline postoperative control cultures of the ethmoid sinus
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Empirical therapy based on baseline culture data
Number of subjects: 113
Study: 11478829

Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.45 g kg(‐1)day(‐1)) for eight weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9929659

Group type: EXPERIMENTAL
Intervention: Butanol delivery during normal respiration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Filtered medical air
Number of subjects: 10
Study: 7798804

Group type: EXPERIMENTAL
Intervention: Plasminogen activation using streptokinase in blood suspensions of diabetic patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Plasminogen activation using streptokinase in blood suspensions of healthy subjects
Number of subjects: 37
Study: 3282895

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31331583

Group type: EXPERIMENTAL
Intervention: 500 mg of Panax Ginseng twice daily for four weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo twice daily for four weeks
Number of subjects: 62
Study: 28364587

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) for OCD, involving family members in two sessions, 12 sessions total.
Number of subjects: 35
Study: 25609546

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS) using adhesive skin surface electrodes for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Solifenacin succinate (SS) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison between PTNS and SS
Number of subjects: 100
Study: 23178737

Group type: EXPERIMENTAL
Intervention: 150 min/week aerobic exercise for four months
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 319
Study: 21865947

Group type: EXPERIMENTAL
Intervention: Mastery Learning (ML)
Number of subjects: 50
Study: 19291551

Group type: EXPERIMENTAL
Intervention: Emergency Medical Services research under exception from informed consent
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Reasons for not enrolling patients in the study
Number of subjects: 844
Study: 16408442

Group type: EXPERIMENTAL
Intervention: Treatment group treated as same as adult patients with diabetes mellitus
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Ordinary treatment group
Number of subjects: 1173
Study: 15329366

Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 1000/100 mg twice-daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 2000/100 mg once-daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: saquinavir/ritonavir 1600/100 mg once-daily
Number of subjects: 20
Study: 10934984

Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various β-Blockers
Number of subjects: 0
Study: 9604580

Group type: EXPERIMENTAL
Intervention: Porcelain veneer restorations
Number of subjects: 180

Group type: COMPARATOR
Intervention: Direct composite veneer restorations
Number of subjects: 180

Group type: COMPARATOR
Intervention: Indirect composite veneer restorations
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 180
Study: 1286547

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily for 4 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 4036846

Group type: EXPERIMENTAL
Intervention: High P/S ratio diet with high cholesterol (1,000 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High P/S ratio diet with low cholesterol (300 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low P/S ratio diet with high cholesterol (1,000 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low P/S ratio diet with low cholesterol (300 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High P/S ratio diet
Number of subjects: 11
Study: 31766333

Group type: EXPERIMENTAL
Intervention: Low Organized Games (LOG) approach in PE (n = 282)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Regular PE (Control group, n = 278)
Number of subjects: 560
Study: 30379732

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymyxins
Number of subjects: 0
Study: 27609406

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 2505

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W)
Number of subjects: 2505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2505

Group type: EXPERIMENTAL
Intervention: Benralizumab (Q4W and Q8W)
Number of subjects: 2505

Group type: EXPERIMENTAL
Intervention: Benralizumab (Q8W only)
Number of subjects: 2505
Study: 25220290

Group type: EXPERIMENTAL
Intervention: 500 ppm F (500 NaF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 NaF CaGP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 MFP CaGP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1100 ppm F (positive control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 NaF CaGP) and 500 ppm F with 0.25% CaGP (500 MFP CaGP)
Number of subjects: 10
Study: 22184611

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL of different concentrations)
Number of subjects: 39
Study: 20705980

Group type: EXPERIMENTAL
Intervention: Tubewells
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Liquid sodium hypochlorite ('Clorin')
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Hygiene promotion
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Combination of tubewells, Clorin, and hygiene promotion
Number of subjects: 2387

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2387
Study: 17434849

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pravastatin (lopinavir/ritonavir subgroup)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (lopinavir/ritonavir subgroup)
Number of subjects: 21
Study: 16318697

Group type: EXPERIMENTAL
Intervention: Antibacterial cleaning products
Number of subjects: 224

Group type: COMPARATOR
Intervention: Nonantibacterial cleaning products
Number of subjects: 224
Study: 12064881

Group type: EXPERIMENTAL
Intervention: Intentional ostectomy of the posterior part of the distal segment (test group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional sagittal split (control group)
Number of subjects: 61
Study: 9524049

Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 50
Study: 7822662

Group type: EXPERIMENTAL
Intervention: Self-management teaching programs
Number of subjects: 23
Study: 2766870

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis with 2 x 2 g ceftriaxone (Rocephin)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis
Number of subjects: 159
Study: 338307

Group type: EXPERIMENTAL
Intervention: Aprindine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31881040

Group type: EXPERIMENTAL
Intervention: ASPREE framework (type-to-search box with automated coding)
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Traditional method (free-text only collection and post hoc coding)
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: ASPREE framework
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 19114
Study: 27669451

Group type: EXPERIMENTAL
Intervention: Combined exercise program (aerobic and resistance) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 26041028

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 23853552

Group type: EXPERIMENTAL
Intervention: Twice weekly iron‐folic acid (IFA)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Twice weekly multiple micronutrient (MMN)
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Daily iron‐folic acid (IFA)
Number of subjects: 1258
Study: 21160152

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Instillagel®) during GIS
Number of subjects: 142

Group type: COMPARATOR
Intervention: Gel without lidocaine (Endosgel®) during GIS
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Instillagel®) during hysteroscopy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Gel without lidocaine (Endosgel®) during hysteroscopy
Number of subjects: 142
Study: 19557003

Group type: EXPERIMENTAL
Intervention: Increased dose of angiotensin‐II receptor blocker (ARB)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Maintenance dose of ARB plus calcium channel blocker (amlodipine)
Number of subjects: 316
Study: 16485881

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream (FC) applied once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream (VC) applied once daily for 7 days
Number of subjects: 0
Study: 15292745

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (INT‐EX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous exercise (CON‐EX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No exercise (NOEX)
Number of subjects: 18
Study: 11069317

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus colchicine
Number of subjects: 65
Study: 9282975

Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction (MPCR) method
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MPCR method with spiked samples
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MPCR method
Number of subjects: 37
Study: 8284632

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily for 3 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 3126024

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy recruitment
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Patient screening and eligibility
Number of subjects: 316
Study: 31174716

Group type: EXPERIMENTAL
Intervention: Advancing Recovery strategies
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no Advancing Recovery strategies)
Number of subjects: 14
Study: 30246694

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU fortnightly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27000224

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 25212062

Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention programme delivered by teachers promoting physical activity and healthy eating; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple methods and tools for data collection including observations, logbooks, qualitative evaluation, questionnaires, and research team reflection; specific outcomes not quantified.
Number of subjects: 0
Study: 22169080

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 9497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Corticosteroid with IMPACT model adjustment
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Corticosteroid with CRASH model adjustment
Number of subjects: 9497
Study: 21142994

Group type: EXPERIMENTAL
Intervention: In virtuo exposure
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting-list condition
Number of subjects: 43
Study: 17643572

Group type: EXPERIMENTAL
Intervention: Atorvastatin alone (single therapy), placebos for ER-niacin and colesevelam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus ER-niacin (2 g/d), placebo for colesevelam (double therapy)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Atorvastatin, ER-niacin, plus colesevelam (3.8 g/d) (triple therapy)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo for ER-niacin and colesevelam (single therapy)
Number of subjects: 123
Study: 15330199

Group type: EXPERIMENTAL
Intervention: Regimen A (Mitomycin, Cisplatin, and Doxifluridine)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Regimen B (Cisplatin and Doxifluridine)
Number of subjects: 61
Study: 11241303

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 918
Study: 9260213

Group type: EXPERIMENTAL
Intervention: Ice water ingestion (250 ml of 0‐4 degrees C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm water ingestion (250 ml of 25 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ice water ingestion in healthy controls (23 children)
Number of subjects: 60
Study: 7671682

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and supination shoe insert
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group of not treated children
Number of subjects: 469
Study: 3812435

Group type: EXPERIMENTAL
Intervention: Educational intervention to improve water-sanitation behaviors
Number of subjects: 1940

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Educational intervention to improve handwashing practices
Number of subjects: 1940